Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tiziana Life Sciences ( (TLSA) ) just unveiled an announcement.
On November 13, 2025, Tiziana Life Sciences announced that its senior leadership team will present at the Jefferies London Healthcare Conference, highlighting their innovative pipeline and recent clinical milestones. The presentation will focus on their lead candidate, intranasal foralumab, which is in clinical development for diseases such as non-active secondary progressive multiple sclerosis and Alzheimer’s. This participation underscores Tiziana’s growing visibility in the biotechnology investment community and its commitment to advancing transformative therapies for patients with high unmet medical needs.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company is known for its innovative nasal approach to immunotherapy, which aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development for treating neuroinflammatory and neurodegenerative diseases.
Average Trading Volume: 341,395
Technical Sentiment Signal: Buy
Current Market Cap: $198.4M
See more data about TLSA stock on TipRanks’ Stock Analysis page.